170862-53-0

Upstream product

• 170862-47-2 (S)-1-(2,4-Difluoro-phenyl)-2-methyl-3-trityloxy-propan-1-one 
• 219872-86-3 propyl (2R,3R)-3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4-triazol-1-yl)butanoate 
• 13292-87-0 dimethyl sulfide borane 
• 166948-49-8 (2R,3R)-3-[3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-3-(1H-1,2,4-triazol-1-yl)]butanoic acid 
• 170862-54-1 (2R,3S)-2-(2,4-difluorophenyl)-3-methyl-4-triphenylmethyloxy-1,2-butanediol 
• 1026233-30-6 Methanesulfonic acid (2R,3S)-2-(2,4-difluoro-phenyl)-2-hydroxy-3-methyl-4-trityloxy-butyl ester 
• 211926-45-3 (2RS,3S)-2-(2,4-difluoro)phenyl-3-methyl-4-triphenylmethyloxy-1,2-epoxybutane 
• 170862-48-3 (S)-2-(2,4-difluorophenyl)-3-methyl-4-(triphenylmethyloxy)-1,2-butene 
• 170862-51-8 (2R,3S)-2-(2,4-Difluoro-phenyl)-3-methyl-1-[1,2,4]triazol-1-yl-4-trityloxy-butan-2-ol 

Downstream Products

• 170862-36-9 (2S,3R)-3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4-triazol-1-yl)butanenitrile 
• 170862-56-3 (2R,3R)-3-(2,4-Difluoro-phenyl)-3-hydroxy-2-methyl-4-[1,2,4]triazol-1-yl-butyraldehyde 

Relevant academic research and scientific papers

Carbon analogs of antifungal dioxane-triazole derivatives: Synthesis and in vitro activities

A new series of triazole compounds possessing a carbon atom in place of a sulfur atom were efficiently synthesized and their in vitro antifungal activities were investigated. The carbon analogs showed excellent in vitro activity against Candida, Cryptococcus, and Aspergillus species. The MICs of compound 1c against C. albicans ATCC24433, C. neoformans TIMM1855, and A. fumigatus ATCC26430 were 0.016, 0.016, and 0.125 μg/mL, respectively (MICs of fluconazole: 0.5, >4, and >4 μg/mL; MICs of itraconazole: 0.125, 0.25, and 0.25 μg/mL).

Azole antifungal agents, processes for the preparation thereof, and intermediates

A compound represented by the general formula: wherein R1 and R2 denote a halogen atom or hydrogen atoms; R3 means a hydrogen atoms or lower alkyl group; r and m stand for 0 or 1; A is N or CH; W denotes an aromatic ring or a condensed ring thereof; X means another aromatic rings, an alkanediyl group, an alkenediyl group, or an alkynediyl group; Y stand for -S-, etc.; Z denotes a hydrogen atom, etc., or a salt thereof, and intermediates thereof or a salt thereof as well as processes for the preparation thereof, and pharmacetical composition suitable for use as an antifungal agent.

AZOLE COMPOUNDS ENDOWED WITH ANTIMYCOTIC ACTIVITY FOR HUMAN AND VETERINARY USE

Compounds of formula wherein R1 is chloro, fluoro, bromo or trifluoromethyl; R2 is hydrogen, chloro , fluoro, bromo or trifluoromethyl; Z is CH or N; R3, R4 and R5, which are the same or different, are hydrogen or C1-C4 alkyl, with the proviso that R4 is

Azole compounds with antimycotic activity for human and veterinary use

Compounds of formula STR1 wherein R1 is chloro, fluoro, bromo or trifluoromethyl; R2 is hydrogen, chloro, fluoro, bromo or trifluoromethyl; Z is CH or N; R3, R4 and R5, which are the same or different

A novel route for chiral synthesis of the triazole antifungal ER-30346

A novel synthetic route to (2S,3S)-2-(2,4-difluorophenyl)-3-hydroxy-2- methyl-4-(1-(1,2,4-triazolyl))butyronitrile (2), an intermediate for the orally active triazole antifungal agent ER-30346, was developed from methyl S-(+)-3-hydroxy-2-methylpropionate,